Extrait

Lenakap : This multicenter, non randomized (single arm), open, phase II study aims to evaluated the efficacy of Lenalidomide in HIV-associated kaposi disease. Patients will be followed for 48 weeks. Measurement of primary endpoint will be at 24 weeks.

Critère d'inclusion

• HIV Infection Associated Kaposi Disease

Liens

• nct
• ictrp